Connect with us

Media OutReach

BeOne Medicines Honored with the Global Oncology Innovation Leadership Award at BIOHK 2025, Supporting “1+” to Accelerate the Delivery of Innovative Cancer Therapies

Published

on

HONG KONG SAR – Media OutReach Newswire – 11 September 2025 – BeOne Medicines (BeOne)(NASDAQ: ONC; HKEX: 06160; SSE: 688235), was honored today at BIOHK 2025, the Hong Kong International Biotechnology Conference & Exhibition, with the prestigious Global Oncology Innovation Leadership Award. This award recognizes BeOne’s outstanding contributions to advancing global oncology research and delivering transformative cancer therapies to patients.

(Leftest) Paul Chan, Financial Secretary; (Fourth from right) Yiya Chen, General Manager (Taiwan, Hong Kong & Macau) of BeOne Medicines

Ms. Yiya Chen, General Manager (Taiwan, Hong Kong & Macau) of BeOne, stated, “Receiving the Global Oncology Innovation Leadership Award not only affirms BeOne’s R&D capabilities, but also motivates us to accelerate the transformation of innovative breakthroughs into tangible benefits for patients in the Greater Bay Area, including Hong Kong. Currently, we offer three novel cancer therapies in Hong Kong, covering BTK inhibitor, PD-1 inhibitor, and IL-6 inhibitor. Moving forward, we will proactively leverage the opportunities under the “1+” mechanism to expedite the importation of more international-standard compliant, self-developed medicines, enabling rapid, extensive access to effective treatment for local cancer patients.

Global Research & Development Together with Powered Innovation
Since its establishment in 2010, BeOne has been upholding its mission of “Cancer has no borders. Neither do we,” focusing on developing high-quality, self-developed medicines that meet international standards, with a commitment to accessibility and affordability of innovative cancer treatments. To date, BeOne has conducted over 170 clinical trials across 45 countries and regions, building one of the world’s largest oncology research teams. More than 1.8 million patients have benefited from the achievements of its research and development.

Diverse Pipeline to Drive Global Impact
BeOne’s R&D spans both hematologic and solid tumors:
  • BTK inhibitor: BeOne’s first independently developed innovative drug, and the only treatment worldwide in its class to have completed head-to-head clinical trials in both Chronic Lymphocytic Leukemia (CLL) and Waldenström’s Macroglobulinemia (WM)1. It has been approved in more than 75 markets and was honored with the prestigious Prix Galien Suisse in 20232..
  • PD-1 inhibitor (immunotherapy): Approved in Hong Kong for six indications, including non-small cell lung cancer, esophageal cancer, and gastric cancer, with expansion to nasopharyngeal carcinoma and lung cancer — two of the most prevalent cancer types in Asia. This therapy is marketed in 47 countries and regions including the United States, European Union, China, and Japan, with over 60 indication-approval applications submitted to expand its global coverage.
Fast-to-Proof of Concept (PoC) Strategy to Accelerate Innovation Delivery
BeOne’s integrated development approach combines robust R&D capabilities, a PoC-driven strategy and a wide portfolio of assets. With over 40 Phase 3-ready or registration-potential clinical trials and more than 40 R&D assets in clinical and commercialization stages, BeOne maintains leadership across multiple technology platforms, including multi-specific antibodies, chimeric degradation activating compounds (CDACs), and antibody-drug conjugates (ADCs).

Through the PoC strategy, BeOne concentrates on highly differentiated and promising molecule candidates. The company has successfully pushed through the clinical development for 20 drug molecules and obtained regulatory approvals across six continents, demonstrating its outstanding R&D efficiency and globalization strategy.

Globalization to Strengthen Sustainable Supply
BeOne has established three major R&D and manufacturing bases in the United States and China, encompassing the entire industry chain from research and development to manufacturing and commercialization. Notably, the Guangzhou campus spans 1.3 million ft2 and features advanced manufacturing capabilities to produce large-molecule drugs, serving as a core supply hub in the Greater Bay Area, including Hong Kong. This footprint ensures a stable drug supply and enhances accessibility for patients in the region.

As one of the world’s top 20 leading oncology patent holders3 and listed as one of the “World’s Top 10 Most Inventive Pharmaceutical Companies”4 by IDEA Pharma in 2025, BeOne will continue to devote its efforts to researching hematologic and solid tumors. Leveraging Hong Kong as a strategic bridge between Asia and the international community, BeOne is committed to accelerating the development and delivery of innovative therapies, collaboratively driving a new paradigm for cancer care regionally and globally.

Prof. Albert Yu, Chairman of Hong Kong Biotechnology Organization, remarked, “BeOne’s leadership in oncology is fully evident in its innovative drug development, globalization strategy, and significant improvements in quality of life for cancer patients locally and worldwide. Grounded in rigorous scientific research, BeOne aligns clinical needs with accessibility considerations across various markets to launch multiple self-developed innovative medicines to the global stage. The company’s efforts represent scientific excellence and a profound commitment to cancer patients, deserving of the Global Oncology Leadership Award.”

This press release contains forward-looking statements, and actual results may differ from those expressed or implied in these statements. All information provided herein is as of the date of this release, and unless required by law, BeOne has no obligation to update or revise any such information.

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential benefits of sonrotoclax; BeOne’s expectations regarding sonrotoclax’s clinical development, regulatory milestones, submissions and approvals; BeOne’s plans to present the full data at an upcoming medical meeting; and BeOne’s plans, commitments, aspirations and goals under the caption “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.


[1] Brown JR, Eichhorst B, Lamanna N, et al. Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Blood. 2024;144(26):2706-2717. doi:10.1182/blood.2024024667
[2] Prix Galien Suisse für Brukinsa, Medical Tribune, 2023
[3] Top 50 Pharma: Oncology patent leaders 2024, Drug Discovery & Development
[4] 2025 Pharmaceutical Innovation and Invention Index, IDEA Pharma

Hashtag: #BeOneMedicines

The issuer is solely responsible for the content of this announcement.

About BeOne Medicines

BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.

To learn more about BeOne, please visit and follow us on , , and .

About BIOHK Hong Kong International Biotechnology Conference & Exhibition

BIOHK Hong Kong International Biotechnology Conference & Exhibition is Asia’s premier biotechnology conference and exhibition. It aims to create a collaborative platform for industry leaders, innovators, and stakeholders to come together and drive the development of biotechnology. BIOHK is dedicated to advancing the biotech sector by not only providing a stage to showcase technological innovations but also offering a launchpad for companies seeking a market expansion to the Greater Bay Area and Mainland China. By combining educational seminars, strategic partnership opportunities, and governmental support, BIOHK empowers participants to foster significant advancements with profound impacts on global health and technology.

Advertisement

Media OutReach

Cyber and Supply Chain Risks Reshaping Japan’s Business Landscape, Aon Survey

Published

on

  • “Geopolitical Volatility” is a top five current and future risk, highlighting the growing instability across the region
  • 83 Percent of Firms Report Rising Insurable Risk Costs

TOKYO, JAPAN – Media OutReach Newswire – 12 February 2026 – Aon plc (NYSE: AON), a leading global professional services firm, has released the Japan findings of its 2025 Global Risk Management Survey. The survey reveals that Japanese businesses are navigating a complex landscape marked by persistent cyber threats, supply chain disruptions and weather/natural disasters. The survey, which gathered insights from nearly 3,000 risk managers, C-suite leaders and executives across 63 countries, highlights the unique risks Japan businesses are facing amid global disruption.

Japan’s Top Risks:

“Cyber Attacks/Data Breach” remains the top risk for Japanese businesses, consistent with global trends. “Supply chain or distribution failure” ranks second, as extreme weather events and mounting geopolitical volatility including shifting trade policies force companies to reassess their supply chains. In addition, “Product Liability/Recall” and “Exchange Rate Fluctuation” pose significant risks, reflecting the country’s manufacturing strength and exposure to global market volatility. Notably, 63.6 percent of Japanese respondents reported losses due to product liability or recall issues and 47.6 percent cited losses from exchange rate fluctuations.

Tatsuya Yamamoto, CEO of Japan at Aon, said, “Japanese organisations are operating in an environment of unprecedented complexity. Cyber, weather and geopolitical risks continue to be acute challenges for Japan businesses, underscoring the need for robust risk management frameworks and agile strategies. As market trends shift and competition intensifies, vigilance and adaptability will be key. The interconnectedness of risks – where a cyber attack can disrupt supply chains or geopolitical volatility can trigger regulatory changes – demands a holistic, proactive approach to resilience.”

2025 Top 10 Business Risks in Japan

  1. Cyber Attacks/Data Breach
  2. Supply Chain or Distribution Failure
  3. Weather/Natural Disasters
  4. Geopolitical Volatility
  5. Business Interruption
  6. Economic Slowdown/Slow Recovery
  7. Exchange Rate Fluctuation
  8. Commodity Price Risk/Scarcity of Materials
  9. Product Liability/Recall
  10. Failure to Attract or Retain Top Talent

Risk Management: Formalisation and Focus on Insurable Risks

Japanese organisations demonstrate a strong commitment to risk management, with 74.7 percent having a formal risk management and insurance department, compared to 68.4 percent globally. Additionally, 75.3 percent measure the total cost of insurable risk and 83.3 percent report that these costs are increasing. While risk awareness is rising, most organisations have yet to quantify their exposures or leverage advanced analytics.

Japanese Businesses Risk Management Assessments for Top Three Risks

For “Cyber Attacks/Data Breaches”:

  1. 27.2 percent have assessed the risk
  2. 12.6 percent have developed continuity plans
  3. 22.3 Percent have risk management plans

For “Supply Chain or Distribution Failure”:

  1. 25 percent have assessed the risk
  2. 20 percent have developed continuity plans
  3. 26.7 Percent have risk management plans

For “Weather/Natural Disasters”:

  1. 24.1 percent have assessed the risk
  2. 22.4 percent have developed continuity plans
  3. 13.8 percent have risk management plans

Future Risks: Rapidly Changing Market Trends and Geopolitical Volatility

Looking ahead, Japanese organisations expect “Weather/Natural Disasters” and “Geopolitical Volatility” to remain critical risks, alongside “Rapidly Changing Market Trends,” which is more prominent in Japan than globally. This highlights the country’s exposure to climate events and evolving consumer preferences.

Japan’s Top Five Future Business Risks by 2028:

  1. Cyber Attacks/Data Breach
  2. Weather/Natural Disasters
  3. Geopolitical Volatility
  4. Rapidly Changing Market Trends
  5. Increasing Competition

Shinichi Kandatsu, head of Commercial Risk Solutions for Japan at Aon, said, “Cyber and weather-related risks continue to lead the rankings as top concerns for Japanese businesses today and in the future, with geopolitical volatility also ranking among the top five risks across both periods. This trend reflects the growing instability across the region, with implications for supply chains, regulatory environments and financial performance. In today’s fast-moving market, leveraging advanced data analytics is essential for businesses to anticipate emerging risks, optimise risk capital and build resilience. The findings from Aon’s Global Risk Management Survey provide Japanese businesses with actionable information to benchmark their risk strategies and identify areas for improvement.”

To access the full report and explore how Aon is helping clients navigate today’s disruption dynamic, visit Global Risk Management Survey Japan

Hashtag: #Aon

The issuer is solely responsible for the content of this announcement.

About Aon

Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that help protect and grow their businesses.

Follow Aon on LinkedIn, X, Facebook and Instagram. Stay up-to-date by visiting Aon’s newsroom and sign up for news alerts here.

Disclaimer

The information contained in this document is solely for information purposes, for general guidance only and is not intended to address the circumstances of any particular individual or entity. Although Aon endeavours to provide accurate and timely information and uses sources that it considers reliable, the firm does not warrant, represent or guarantee the accuracy, adequacy, completeness or fitness for any purpose of any content of this document and can accept no liability for any loss incurred in any way by any person who may rely on it. There can be no guarantee that the information contained in this document will remain accurate as on the date it is received or that it will continue to be accurate in the future. No individual or entity should make decisions or act based solely on the information contained herein without appropriate professional advice and targeted research.

Continue Reading

Media OutReach

Sustainable seafood matters to eight in ten consumers, leading to calls for retailers to support sustainable choices

Published

on

MSC calls on retailers to increase their offer of sustainable seafood products ahead of the Chinese New Year, in response to insights from consumers

SINGAPORE – Media OutReach Newswire – 12 February 2026 – As families across Singapore and Malaysia prepare to toss yusheng and serve whole steamed fish for Chinese New Year, new research reveals a striking disconnect: more than eight in ten Malaysians (85%) and nearly three-quarters of Singaporeans (74%) say sustainable seafood matters to them.

Despite actively seeking out sustainable sources, a YouGov survey commissioned by the Marine Stewardship Council (MSC) found that more than half of Singapore consumers (58%) have never noticed an eco-label when shopping. Recognition of the MSC blue ecolabel label sits at 21%.

With seafood consumption expected to rise during Chinese New Year as celebrations take centre stage, it’s a critical moment for sustainable shopping choices.

Malaysia consumes more than double the global average per capita (49 kg versus 21 kg globally), while Singapore imports most of its seafood supply. Without clear labelling and retailer commitment, consumers who want to make sustainable choices often cannot.

In Malaysia, where fishing remains central to coastal livelihoods, 75% of Malaysians believe support and resources are essential for local fishermen to fish responsibly and sustainably.

In Singapore, where nearly all seafood is imported, consumers look to retailers and regulators for assurance, with 55% citing government standards and 54% citing origin information as key drivers of confidence.

“When asked what sustainable seafood means to them, consumers demonstrated a sophisticated understanding: 62% of Singaporeans and 56% of Malaysians associate it with well-managed fisheries operating under clear rules.

“It’s clear that consumers are ready and willing to seek out credible certification, so we’re urging retailers and businesses to make MSC eco-label products visible and accessible,” saidAnne Gabriel, Program Director for Oceania and Singapore at the Marine Stewardship Council.

The research also highlights expectations of retailers. More than half of Singaporeans (52%) believe supermarkets should commit to sourcing sustainable seafood. Even amid cost-of-living pressures, 38% say they are willing to pay more for sustainably sourced seafood, while many others say clear labelling would help them make better choices within their budget.

The findings suggest that as festive demand peaks, clearer eco-labelling could help consumers align their values with their shopping – without changing what’s on the dinner table.

Shoppers can find MSC certified sustainable seafood at Cold Storage Singapore, FairPrice Group and Prime Supermarket in Singapore, and at AEON Retail, Jaya Grocer and Village Grocer in Malaysia.

Key findings at a glance

  • 85% of Malaysians and 74% of Singaporeans say sustainable seafood is important
  • 63% (MY) and 58% (SG) have never noticed any eco-label on seafood
  • 75% of Malaysians believe fishermen need support to fish sustainably
  • 52% Singaporeans say retailer commitment to sustainable sourcing would encourage them to choose sustainable seafood
  • Malaysia consumes 49kg of seafood per capita annually vs 21kg global average, sources from Malaysia – Fishery and Aquaculture Country Profiles

About the research
The survey was conducted by YouGov on behalf of the Marine Stewardship Council between 15-19 January 2026. The sample comprised 1,007 adults aged 18+ in Singapore and 1,003 adults aged 18+ in Malaysia. Data was weighted to be representative of the adult population in each country.
Hashtag: #TheMarineStewardshipCouncil #MSC

The issuer is solely responsible for the content of this announcement.

About the Marine Stewardship Council (MSC)

The Marine Stewardship Council (MSC) is an international non-profit organisation. Our vision is of the world’s oceans teeming with life, and seafood supplies safeguarded for this and future generations. Our blue fish ecolabel and fishery certification program recognises and rewards sustainable fishing practices. When you see the blue fish label, you can trust the seafood was caught sustainably. For more information visit

Continue Reading

Media OutReach

ATPI Strengthens Taiwan Presence with Award-Winning Travel Management Solution

Published

on

2025 Global Travel Management Company of the Year recognition affirms ATPI’s leadership in localised, enterprise-ready travel management

TAIPEI, TAIWAN – Media OutReach Newswire – 12 February 2026 – ATPI Taiwan continues to strengthen its position as a trusted global travel management partner for organisations operating in Taiwan, following the recognition of ATPI’s Hong Kong and Singapore operations as Global Travel Management Company of the Year at the Travel Daily Media Travel Trade Excellence Awards 2025.

Photo caption: (Left to Right) Kelly Jones, Managing Director of ATPI Taiwan; Gary Marshall, CEO of Travel Daily Media; and Ali Hussain, Managing Director of ATPI Asia, at the TDM Travel Trade Excellence Awards 2025 – Asia

The Travel Daily Media Travel Trade Excellence Awards – Asia recognises organisations demonstrating excellence in operational delivery, technology integration and service innovation. ATPI was recognised for its ability to deliver globally integrated travel programmes supported by personalised service, secure platforms and disciplined governance across complex, multi-market environments.

Building on these globally recognised capabilities, ATPI Taiwan operates as a professional travel management organisation purpose-built for multinational and technology-driven enterprises. Its local operating model addresses key structural gaps in Taiwan’s corporate travel landscape, where many providers remain leisure-focused and reliant on manual processes that limit transparency, control and scalability.

A defining differentiator is financial transparency. Unlike traditional agencies that issue a single “all-in” receipt, ATPI Taiwan provides two separate documents:

  • a Travel Agency Receipt detailing the net ticket fare; and
  • a Government Uniform Invoice (GUI / 發票) clearly itemising the agreed service fee.

ATPI is currently the only travel management company in Taiwan offering this structure. The model enables procurement and finance teams to perform audit-level cost analysis, eliminates hidden mark-ups and supports compliance requirements for publicly listed, multinational and technology-led organisations.

ATPI Taiwan’s cloud-based global travel management platform integrates directly with ATPI’s worldwide traveller profile and governance framework. This enables organisations to enforce consistent travel policies, approval workflows and duty-of-care standards across Taiwan and international markets. Centralised dashboards provide real-time visibility of both Taiwan and global travel spend, supporting procurement oversight, financial control and data-driven decision-making for high-volume international travel programmes.

Data security is another critical differentiator. While traveller information in Taiwan is often collected via unsecured consumer messaging platforms, ATPI Taiwan operates in line with ATPI Global Standards and international data protection protocols. Traveller data is managed through the ATPI e-Profile platform, supported by PCI-compliant secure links for document submission and mandatory quarterly data-security training. To date, ATPI Taiwan has maintained a zero data-misconduct and zero data-leakage record.

ATPI also provides professional 24/7 global emergency support through its World Support Centres (WSC), ensuring continuity across time zones with full system access and defined escalation protocols — capabilities essential for mission-critical and time-sensitive travel.

“Our focus is on delivering enterprise-grade travel management that combines global consistency with local precision,” said Kelly Jones, Managing Director – Southeast Asia, China, Hong Kong & Taiwan, ATPI. “Clients choose ATPI not only for our global reach, but for the governance, transparency and personalised service that allow their travel programmes to operate with confidence and control.”

“These capabilities translate directly into measurable outcomes for our clients,” added Asa Yang, General Manager, ATPI Taiwan. “In one recent case, our team conducted a strategic fare analysis for a complex five-destination itinerary and identified a more cost-effective routing. Instead of retaining the price differential, we returned 100% of the savings to the client, delivering a direct saving of TWD 160,000. This reflects our commitment to financial transparency, integrity and proactive programme management.”

The dual awards further reinforce ATPI’s long-standing leadership in corporate and specialist travel management. Following ATPI’s acquisition by Direct Travel in September 2025, the combined organisation operates as a global travel management group, bringing together international scale and personalised service across corporate and complex travel sectors, including marine, energy, mining, sports and group travel. Together, Direct Travel and ATPI manage more than USD 6 billion in annual travel volume, with operations spanning over 100 countries across the Americas, Europe, Asia Pacific, Africa and the Middle East.

Hashtag: #atpi #corporatetravelmanagement


The issuer is solely responsible for the content of this announcement.

About ATPI

is a global leader in travel and event management, renowned for delivering innovative and highly tailored solutions across various industries including corporate, marine, mining, energy, sports, and group travel as well as event management services. Founded in 2002 and headquartered in Manchester, UK, ATPI employs approximately 2,500 people and has an operations network that spans across 100+ locations on six continents. Their robust global footprint, combined with deep local expertise, allows them to meet the unique and complex needs of a diverse clientele.

In September 2025, ATPI was acquired by longstanding partner Direct Travel to create a global Travel Management powerhouse.

About Direct Travel, Inc.

Direct Travel is one of the world’s largest travel management companies, focused on delivering exceptional, groundbreaking solutions to every client and traveller. With a long history of proven market expertise, we blend advanced technology, superior service, and expert insights to drive tangible value and meaningful savings—offering solutions across Corporate Travel, Leisure Travel, and Meetings & Events.

Through Avenir, our next-generation platform developed with leading technology partners, we provide the industry’s broadest inventory and a modern, real-time shopping experience that empowers travellers and simplifies programme management. What truly sets us apart is the human care behind the technology: an experienced, passionate team dedicated to anticipating needs and delivering exceptional service at every step.

For more information, visit.

Continue Reading

Trending